The survey that mapped where PSMA is found in the body, and showed it is almost nowhere except the prostate, which is what makes it safe to aim a radioactive drug at it.
An extensive immunohistochemical analysis was performed on a panel of well-characterised normal and malignant human tissues to define the pattern of prostate-specific membrane antigen expression. Detectable levels were identified in prostatic epithelium, duodenal mucosa and a subset of proximal renal tubules, and a subpopulation of neuroendocrine cells in the colonic crypts also showed immunoreactivity; all other normal tissues, including cerebral cortex and cerebellum, had undetectable levels. Thirty-three of 35 primary prostate adenocarcinomas and 7 of 8 lymph node metastases showed tumour cell staining, while 8 of 18 prostate tumours metastatic to bone expressed it. All other non-prostatic primary tumours studied had undetectable levels, but intense staining was seen in capillary endothelial cells in peritumoral and endotumoral areas of certain malignancies, including 8 of 17 renal cell carcinomas, 7 of 13 transitional cell carcinomas and 3 of 19 colon carcinomas. The decrease in immunoreactivity in advanced prostate cancer suggested that expression is linked to the degree of tumour differentiation.
It is the anatomical basis for PSMA imaging and PSMA radioligand therapy, and it predicted two of the practical problems three decades early: salivary, lacrimal and renal uptake as sources of toxicity, and falling expression in dedifferentiated disease as the reason some men are ineligible for treatment.
Shares PSMA expression by PET (PSMA-positive), Theranostics, Prostate cancer (KEGG map), PSMA.
Shares PSMA expression by PET (PSMA-positive), Theranostics, Prostate cancer (KEGG map), PSMA.
Shares PSMA expression by PET (PSMA-positive), Theranostics, PSMA, PSMA PET.
Shares PSMA expression by PET (PSMA-positive), Theranostics, PSMA, PSMA PET.
Shares Theranostics, PSMA, PSMA PET, Radioligand therapy (beta emitters).
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares PSMA expression by PET (PSMA-positive), PSMA, PSMA PET, Radioligand therapy (beta emitters).
Shares Theranostics, PSMA, PSMA PET, Radioligand therapy (beta emitters).